Enochian

Bragar Eagel & Squire, P.C. Is Investigating RBB, Agrify, Carvana, and Enochian and Encourages Investors to Contact the Firm

Retrieved on: 
Monday, July 11, 2022
EVP, News, United, CEO, District, NYSE, Carvana, Death, RBB, GLOBE, Royal Business Bank, NASDAQ, Security (finance), Audit, Property management, P.C, Enochian

Our investigations concern whether these companies have violated the federal securities laws and/or engaged in other unlawful business practices.

Key Points: 
  • Our investigations concern whether these companies have violated the federal securities laws and/or engaged in other unlawful business practices.
  • Dr. Gumrukcu sold 253,493 shares of Enochian stock on May 18, 2022, for a total value of over $2 million.
  • For more information on the Enochian investigation go to: https://bespc.com/cases/ENOB
    About Bragar Eagel & Squire, P.C.
  • The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country.

Kirby McInerney LLP Announces an Investigation of Shareholder Claims Against Enochian Biosciences, Inc. (ENOB)

Retrieved on: 
Thursday, July 7, 2022
Class Action Lawsuit, Professional Services, Legal, Review, Kirby, Justice, Cancer, The Wall Street Journal, Company, Research report, Hindenburg Research, Privacy Office of the U.S. Department of Homeland Security, Hindenburg, U.S. Department of Justice Office of Legislative Affairs, NASDAQ, FBI, News, Private investigator, Pharmaceutical industry, Enochian

The law firm of Kirby McInerney LLP is investigating potential claims against Enochian Biosciences, Inc. (Enochian or the Company) (NASDAQ: ENOB ).

Key Points: 
  • The law firm of Kirby McInerney LLP is investigating potential claims against Enochian Biosciences, Inc. (Enochian or the Company) (NASDAQ: ENOB ).
  • The investigation concerns whether Enochian has violated the federal securities laws and/or engaged in other unlawful business practices.
  • Enochian is a biopharmaceutical company that focuses on identifying, developing, manufacturing, and commercializing gene-modified cell therapy.
  • Kirby McInerney LLP is a New York-based plaintiffs law firm concentrating in securities, antitrust, whistleblower, and consumer litigation.

Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Continues Investigation of Enochian Biosciences, Inc. (ENOB) on Behalf of Investors

Retrieved on: 
Wednesday, July 6, 2022
Class Action Lawsuit, Professional Services, Legal, Insurance, Review, FDA, Justice, Associated Press, SCAS, Press, Bloomberg Businessweek, Cancer, The Wall Street Journal, Company, Research report, Industry, Hindenburg Research, Financial Times, Publication, Office of Inspector General, U.S. Department of Health and Human Services, Real estate investment trust, GPM, Person, SEC, Hindenburg, U.S. Department of Justice Office of Legislative Affairs, NASDAQ, FBI, News, Information technology, Program, DOJ, Medical device, Pharmaceutical industry, Nightclub, Enochian, Forbes, Reuters

Glancy Prongay & Murray LLP (GPM), a leading national shareholder rights law firm, continues its investigation on behalf of Enochian Biosciences, Inc. (Enochian or the Company) (NASDAQ: ENOB ) investors concerning the Companys possible violations of the federal securities laws.

Key Points: 
  • Glancy Prongay & Murray LLP (GPM), a leading national shareholder rights law firm, continues its investigation on behalf of Enochian Biosciences, Inc. (Enochian or the Company) (NASDAQ: ENOB ) investors concerning the Companys possible violations of the federal securities laws.
  • On this news, Enochians stock fell $2.17, or 37%, to close at $3.70 per share on May 25, 2022, thereby injuring investors.
  • On this news, Enochians stock fell $1.49, or 28.4%, to close at $3.77 on June 1, 2022, thereby injuring investors further.
  • Glancy Prongay & Murray LLP is a premier law firm representing investors and consumers in securities litigation and other complex class action litigation.

INVESTOR ALERT: Law Offices of Howard G. Smith Continues Investigation of Enochian Biosciences, Inc. (ENOB) on Behalf of Investors

Retrieved on: 
Wednesday, July 6, 2022
Class Action Lawsuit, Professional Services, Legal, Review, Justice, Cancer, The Wall Street Journal, Company, Research report, Suite, Hindenburg Research, Telephone, Office of Inspector General, U.S. Department of Health and Human Services, Hindenburg, U.S. Department of Justice Office of Legislative Affairs, NASDAQ, FBI, News, Pharmaceutical industry, Nightclub, Enochian

Law Offices of Howard G. Smith continues its investigation on behalf of Enochian Biosciences, Inc. (Enochian or the Company) (NASDAQ: ENOB ) investors concerning the Companys possible violations of federal securities laws.

Key Points: 
  • Law Offices of Howard G. Smith continues its investigation on behalf of Enochian Biosciences, Inc. (Enochian or the Company) (NASDAQ: ENOB ) investors concerning the Companys possible violations of federal securities laws.
  • On this news, Enochians stock fell $2.17, or 37%, to close at $3.70 per share on May 25, 2022, thereby injuring investors.
  • On this news, Enochians stock fell $1.49, or 28.4%, to close at $3.77 on June 1, 2022, thereby injuring investors further.
  • This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

The Law Offices of Frank R. Cruz Continues Investigation of Enochian Biosciences, Inc. (ENOB) on Behalf of Investors

Retrieved on: 
Tuesday, July 5, 2022
Class Action Lawsuit, Professional Services, Legal, Review, Law, Justice, Cancer, The Wall Street Journal, Company, Research report, Suite, Hindenburg Research, Office of Inspector General, U.S. Department of Health and Human Services, Hindenburg, U.S. Department of Justice Office of Legislative Affairs, NASDAQ, FBI, Twitter, News, Pharmaceutical industry, Nightclub, Enochian

The Law Offices of Frank R. Cruz continues its investigation of Enochian Biosciences, Inc. (Enochian or the Company) (NASDAQ: ENOB ) on behalf of investors concerning the Companys possible violations of federal securities laws.

Key Points: 
  • The Law Offices of Frank R. Cruz continues its investigation of Enochian Biosciences, Inc. (Enochian or the Company) (NASDAQ: ENOB ) on behalf of investors concerning the Companys possible violations of federal securities laws.
  • On May 25, 2022, the U.S. Department of Justice announced that Serhat Gumrukcu, the inventor and co-founder of Enochian, had been arrested and charged in a murder-for-hire conspiracy.
  • On this news, Enochians stock fell $2.17, or 37%, to close at $3.70 per share on May 25, 2022, thereby injuring investors.
  • On this news, Enochians stock fell $1.49, or 28.4%, to close at $3.77 on June 1, 2022, thereby injuring investors further.

Bragar Eagel & Squire, P.C. Is Investigating Enochian, Corcept, Rollins, and Target and Encourages Investors to Contact the Firm

Retrieved on: 
Tuesday, July 5, 2022
Documentation, Review, CORT, Annual report, Death, Period. End of Sentence., TGT, Corcept Therapeutics, U.S. Securities and Exchange Commission, Target, GLOBE, Accountability Act, Sale, Company, Health Insurance Portability and Accountability Act, Record, HIPAA, United, District, NYSE, Rollins, SEC, NASDAQ, News, Income, Target Corporation, Private investigator, Online gambling, Audit, Renewable energy, Enochian, P.C

Our investigations concern whether these companies have violated the federal securities laws and/or engaged in other unlawful business practices.

Key Points: 
  • Our investigations concern whether these companies have violated the federal securities laws and/or engaged in other unlawful business practices.
  • On this news, Enochians stock fell $2.17, or 37%, to close at $3.70 per share on May 25, 2022.
  • Dr. Gumrukcu sold 253,493 shares of Enochian stock on May 18, 2022, for a total value of over $2 million.
  • For more information on the Target investigation go to: https://bespc.com/cases/TGT
    About Bragar Eagel & Squire, P.C.

Enochian BioSciences Announces Findings From A Rigorous Internal Review of Scientific Data

Retrieved on: 
Friday, July 1, 2022
Review, Acquisition, Annual report, Hepatitis, GLOBE, HBV, COVID-19, Company, Subclinical infection, Public health, Employment, List, HIV, SEC, NASDAQ, Board, Conference on Retroviruses and Opportunistic Infections, Hepatitis B virus, Nature, Conference, Pharmaceutical industry, Enochian

LOS ANGELES, July 01, 2022 (GLOBE NEWSWIRE) -- (NASDAQ: ENOB)In recent days, Enochian BioSciences (the Company) has conducted a rigorous internal review of scientific data to give partners and investors a clear understanding of the Companys pipelines.

Key Points: 
  • LOS ANGELES, July 01, 2022 (GLOBE NEWSWIRE) -- (NASDAQ: ENOB)In recent days, Enochian BioSciences (the Company) has conducted a rigorous internal review of scientific data to give partners and investors a clear understanding of the Companys pipelines.
  • These data, combined with similar promising data for the treatment of Hepatitis B Virus (HBV), were the basis for the Companys acquisition of the COVID-19 and influenza intellectual property.
  • However, during the review, the Company discovered that former scientific advisor Serhat Gumruku altered two different sets of animal data generated by third-party research institutions before Enochians scientists had a chance to review.
  • The Company is evaluating its internal controls regarding the review and verification of external scientific data and will modify as appropriate.

Bragar Eagel & Squire, P.C. Is Investigating Agrify, Carvana, Enochian, and Corcept and Encourages Investors to Contact the Firm

Retrieved on: 
Thursday, June 30, 2022
CORT, Death, Corcept Therapeutics, GLOBE, Accountability Act, Sale, Company, U.S. Securities and Exchange Commission, Health Insurance Portability and Accountability Act, Record, HIPAA, United, District, NYSE, Carvana, NASDAQ, News, Therapy, Online gambling, Animal, Audit, Enochian, P.C

Our investigations concern whether these companies have violated the federal securities laws and/or engaged in other unlawful business practices.

Key Points: 
  • Our investigations concern whether these companies have violated the federal securities laws and/or engaged in other unlawful business practices.
  • On this news, Agrifys common stock price fell sharply during intraday trading on December 16, 2021.
  • For more information on the Corcept investigation go to: https://bespc.com/cases/CORT
    About Bragar Eagel & Squire, P.C.
  • The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country.

Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Continues Investigation of Enochian Biosciences, Inc. (ENOB) on Behalf of Investors

Retrieved on: 
Wednesday, June 29, 2022
Class Action Lawsuit, Professional Services, Legal, Insurance, FDA, Justice, Associated Press, SCAS, Press, Bloomberg Businessweek, Cancer, The Wall Street Journal, Research report, Industry, Hindenburg Research, Financial Times, Publication, Office of Inspector General, U.S. Department of Health and Human Services, Real estate investment trust, GPM, Person, SEC, Hindenburg, U.S. Department of Justice Office of Legislative Affairs, NASDAQ, FBI, News, Information technology, Program, DOJ, Pharmaceutical industry, Nightclub, Enochian, Forbes, Reuters

Glancy Prongay & Murray LLP (GPM), a leading national shareholder rights law firm, continues its investigation on behalf of Enochian Biosciences, Inc. (Enochian or the Company) (NASDAQ: ENOB ) investors concerning the Companys possible violations of the federal securities laws.

Key Points: 
  • Glancy Prongay & Murray LLP (GPM), a leading national shareholder rights law firm, continues its investigation on behalf of Enochian Biosciences, Inc. (Enochian or the Company) (NASDAQ: ENOB ) investors concerning the Companys possible violations of the federal securities laws.
  • On this news, Enochians stock fell $2.17, or 37%, to close at $3.70 per share on May 25, 2022, thereby injuring investors.
  • On this news, Enochians stock fell $1.49, or 28.4%, to close at $3.77 on June 1, 2022, thereby injuring investors further.
  • Glancy Prongay & Murray LLP is a premier law firm representing investors and consumers in securities litigation and other complex class action litigation.

INVESTOR ALERT: Law Offices of Howard G. Smith Continues Investigation of Enochian Biosciences, Inc. (ENOB) on Behalf of Investors

Retrieved on: 
Tuesday, June 28, 2022
Class Action Lawsuit, Professional Services, Legal, Justice, Cancer, The Wall Street Journal, Research report, Suite, Hindenburg Research, Telephone, Office of Inspector General, U.S. Department of Health and Human Services, Hindenburg, U.S. Department of Justice Office of Legislative Affairs, NASDAQ, FBI, News, Pharmaceutical industry, Nightclub, Enochian

Law Offices of Howard G. Smith continues its investigation on behalf of Enochian Biosciences, Inc. (Enochian or the Company) (NASDAQ: ENOB ) investors concerning the Companys possible violations of federal securities laws.

Key Points: 
  • Law Offices of Howard G. Smith continues its investigation on behalf of Enochian Biosciences, Inc. (Enochian or the Company) (NASDAQ: ENOB ) investors concerning the Companys possible violations of federal securities laws.
  • On this news, Enochians stock fell $2.17, or 37%, to close at $3.70 per share on May 25, 2022, thereby injuring investors.
  • On this news, Enochians stock fell $1.49, or 28.4%, to close at $3.77 on June 1, 2022, thereby injuring investors further.
  • This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.